The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.


  • Type: Antibiotic (cephalosporin/beta-lactamase inhibitor combination)
  • Dosage Forms: IV
  • Common Trade Names: Zerbaxa

Adult Dosing

  • 1.5 grams (1gm ceftolozane/0.5gm tazobactam) IV q8H

Pediatric Dosing

Safety/efficacy not established in children

Special Populations

  • Pregnancy Rating: B
  • Lactation: Infant risk cannot be ruled out
  • Renal Dosing: 750mg IV q8hr for moderate renal impairment, 375mg IV q8hr for severe impairment
  • Hepatic Dosing: no adjustment


  • Allergy to class/drug

Adverse Reactions


  • C. difficile diarrhea
  • Renal impairment
  • Hypersensitivity


  • Nausea, diarrhea
  • Headache
  • Fever


  • Half-life: Ceftolozane- ~3h, Tazobactam- ~1h
  • Metabolism: N/A
  • Excretion: Renal (100%)

Mechanism of Action

  • Ceftolozane: cephalosporin- binds to bacterial PCN-binding proteins, thus inhibiting bacterial cell wall synthesis
  • Tazobactam: irreversibly inhibits some penicillinases and cephalosporinases and binds to some chromosomal and plasmid-mediated bacterial beta-lactamases